Drug Trial Radar · NCT03673943
Imaging of Patients With Known or Suspected Somatostatin Receptor Positive Neuroendocrine Tumors Using Cu64-DOTATATE
Last checked: Nov 20, 2026Latest source record: Dec 22, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
63
Actual
Start
Aug 23, 2018
Primary completion
Mar 23, 2019
Study completion Aug 7, 2019
Sponsor
- Lead sponsor
- Radiomedix, Inc.Industry
- Sponsor type
- Industry
- First posted
- Sep 17, 2018
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Diagnostic
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is an open-label, single-dose, single-arm, single-center imaging study using DOTATATE peptide, labelled with the 64Cu tracer.
Conditions
- Neuroendocrine Tumors
Interventions
64Cu-DOTATATEDrug
Detection of somatostatin positive lesions in NET
Primary outcomes
What the sponsor says the trial is designed to measure.
- Sensitivity of 64Cu-DOTATATE PET-CT Imaging for Detection of Somatostatin Receptor Positive SSTR (+) TumorTime frame: 12 months
- Specificity of 64Cu- DOTATATE PET/CT Imaging for Detection of Neuroendocrine TumorTime frame: 12 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Excel Diagnostics and Nuclear Oncology Center
Houston, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.